Blueprint Medicines (BPMC) Competitors

Summit Therapeutics (NASDAQ:SMMT) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Do institutionals and insiders hold more shares of SMMT or BPMC?

4.6% of Summit Therapeutics shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts recommend SMMT or BPMC?

Summit Therapeutics currently has a consensus target price of $35.40, indicating a potential upside of 4.65%. Blueprint Medicines has a consensus target price of $124.95, indicating a potential upside of 46.67%. Given Blueprint Medicines' higher possible upside, analysts plainly believe Blueprint Medicines is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Is SMMT or BPMC more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Blueprint Medicines' return on equity of -77.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-85.42%	-52.66%
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Does the media favor SMMT or BPMC?

In the previous week, Blueprint Medicines had 13 more articles in the media than Summit Therapeutics. MarketBeat recorded 24 mentions for Blueprint Medicines and 11 mentions for Summit Therapeutics. Blueprint Medicines' average media sentiment score of 0.88 beat Summit Therapeutics' score of 0.69 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	11 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, SMMT or BPMC?

Blueprint Medicines has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	$700K	35,646.81	-$614.93M	-$0.31	-109.12
Blueprint Medicines	$508.82M	10.70	-$67.09M	-$1.08	-78.88

Does the MarketBeat Community prefer SMMT or BPMC?

Blueprint Medicines received 242 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 68.19% of users gave Blueprint Medicines an outperform vote while only 58.52% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Summit Therapeutics	Outperform Votes 309 58.52%	Underperform Votes 219 41.48%
Blueprint Medicines	Outperform Votes 551 68.19%	Underperform Votes 257 31.81%

Which has more risk and volatility, SMMT or BPMC?

Summit Therapeutics has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.

Summary

Blueprint Medicines beats Summit Therapeutics on 13 of the 19 factors compared between the two stocks.